Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553706 | 1.00 | CYP2D6 (0.52) | CYP2D6TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6946798 | 0.93 | CYP2D6 (0.47) | CYP2D6TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6952239 | 0.93 | CYP2D6 (0.47) | CYP2D6TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6952074 | 0.93 | CYP2D6 (0.47) | CYP2D6TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6952212 | 0.91 | CYP2D6 (0.45) | CYP2D6TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL21987714 | 0.90 | CYP2D6 (0.52) | CYP2D6TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL28435940 | 0.87 | TSHR (0.59) | CYP2D6TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL28896946 | 0.87 | TSHR (0.59) | CYP2D6TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6945808 | 0.86 | CHRNA7 (0.44) | CYP2D6TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6948689 | 0.86 | CHRNA7 (0.44) | CYP2D6TSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| CN-111566102-B | Substituted pyrrolopyridines as activin receptor-like kinase inhibitors | 缆图药品公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-110691773-B | Substituted indoline derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| WO-2023069547-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3697786-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2022-08-31 | — | — | EP | disclosed |
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3894004-A1 | CHROMAN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-10-20 | — | — | EP | disclosed |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3560925-B1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-20190010135-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| EP-3148963-B1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3148963-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| US-20120189546-A1 | Radiolabelling Method Using Cycloalkyl Groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| EP-2454230-A1 | RADIOLABELLING METHOD USING CYCLOALKYL GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006621-A1 | RADIOLABELLING METHOD USING CYCLOALKYL GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | CYP2D6 2976/4885TSHR 2300/4885ALDH1A1 1467/4885 |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | CYP2D6 3088/4885TSHR 2142/4885ALDH1A1 1572/4885 |
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | ALK, ACVR1, ACVR2A | CYP2D6 3048/4885TSHR 1598/4885ALDH1A1 3502/4885 |
| US-20120189546-A1 | Radiolabelling Method Using Cycloalkyl Groups | TMEM14C, PAICS, QPCT | CYP2D6 1432/4885TSHR 1620/4885ALDH1A1 3286/4885 |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | CYP2D6 3107/4885TSHR 2448/4885ALDH1A1 1449/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | CYP2D6 28/4885TSHR 3525/4885ALDH1A1 1584/4885 |
| US-20190010135-A1 | Novel Compounds | CXCR2, CXCR1, CXCR3 | CYP2D6 2066/4885TSHR 2718/4885ALDH1A1 1918/4885 |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | CCR1, SSB, C5 | CYP2D6 1987/4885TSHR 1153/4885ALDH1A1 623/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | CYP2D6 1987/4885TSHR 1153/4885ALDH1A1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.